|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Safety and efficacy of ledipasvir/sofosbuvir on hepatitis C eradication in hepatitis C virus/human immunodeficiency virus co-infected patients显示文摘AIM To evaluate the safety and efficacy of ledipasvir/sofosbuvir on hepatitis C eradication in patients with hepatitis C virus(HCV)/human immunodeficiency virus(HIV) co-infection in an urban HIV clinic.METHODS A retrospective cohort study of 40 subjects co-infected with HIV-1 and HCV treated with the fixed-dose combination of ledipasvir and sofosbuvir for 12 wk from 2014 to 2016.All patients included were receiving antiretroviral therapy(ART) with HIV RNA values of 100 copies/m L or fewer regardless of baseline HCV RNA level.The primary end point was a sustained virologic response of HCV at 12 wk(SVR12) after the end of therapy.RESULTS Of the 40 patients enrolled,55% were black,22.5% had been previously treated for HCV,and 25% hadcirrhosis.The patients were on a wide range of ART.Overall,39 patients(97.5%) had a SVR 12 after the end of therapy,including rates of 97.1% in patients with HCV genotype 1 a and 100% in those with HCV genotype 1 b.One patient with HCV genotype 3 a was included and achieved SVR12.Rates of SVR12 were similar regardless of previous treatment or the presence of compensated cirrhosis.Only 1 patient experienced relapse at week 12 following treatment and deep sequencing didn't reveal any resistance associated mutation in the NS5A or NS5B region.Interestingly,7(17.5%) patients who were adherent to ART experienced HIV viral breakthrough which resolved after continuing the same ART regimen.Two(5%) patients experienced HIV-1 virologic rebound due to noncompliance with HIV therapy,which resolved after resuming the same ART regimen.No severe adverse events were observed and no patient discontinued treatment because of adverse events.The most common adverse events included headache(12.5%),fatigue(10%),and diarrhea(2.5%).CONCLUSION This retrospective study demonstrated the high rates of SVR12 of ledipasvir/sofosbuvir on HCV eradication in patients co-infected with HCV and HIV,regardless of HCV baseline levels,HCV treatment history or cirrhosis condition.The oral combination of ledipasvir/sofosbuvir represents a safe and well tolerated HCV treatment option that does not require modification for many of the common HIV ART.Occasional HIV virologic rebound occurred but later resolved without the need to change ART. | Xiaoping He Lynne Hopkins George Everett Willie M Carter Cynthia SchroppDyce Khalid Abusaada Vincent Hsu | 2017 | World Journal of Hepatology2017，9，30： | 2 |
| 2 | Adaptive denoising based on SURE risk显示文摘 | Zhang Xiaoping M D Desai | 1985 | IEEE Signal Processing Letters1985，5，10： | 1 |
| 3 | Adaptive de - noising based on SURE risk 显示文摘 | Zhang Xiaoping Desai M D | 1998 | IEEE Signal Processing Lenders1998，5，10： | 1 |
| 4 | Improved cellulose dyeability by chemical modification of the fiber显示文摘 | LEWIS David M LEI Xiaoping | 1989 | Reactive Dyes1989，21，10： | 1 |
| 5 | Adaptive denoising based on SURE risk 显示文摘 | Zhang Xiaoping Desai M D | 1998 | IEEE Signal Processing Letters1998，5，10： | 1 |
| 6 | Soil microbial biomass, crop yields, and bacterial community structure as affected by long-term fertilizer treatments under wheat-rice cropping显示文摘 | Yunfu Gu Xiaoping Zhang Shihua Tu Kristina Lindstr?m | 2009 | European Journal of Soil Biology2009，，3： | 1 |
| 7 | Adaptive Denoising Based on SURE Risk 显示文摘 | Zhang Xiaoping Desai M D | 1998 | IEEE Signal Processing Lerrers1998，5，10： | 1 |
| 8 | A quantitative assessment of the efficacy of an environmental enrichment programme for giant pandas显示文摘 | Swaisgood Angela M White Xiaoping Zhou | 2001 | Animal Behaviour2001，61，： | 1 |
| 9 | Pemxisome proliferator-acti- vated receptor activators target human eendothelial ceils to inhibit leukocyte-endothelial cell interaction 显示文摘 | Jackon S M Parhami F Xi Xiaoping | 1999 | Arterioscler Thromb Vasc Bi- ol1999，19，： | 1 |
| 10 | Adaptive de-noising based on SURE risk显示文摘 | Zhang Xiaoping Desai M D | 1998 | IEEE Signal Processing Letters1998，5，10： | 1 |
| 11 | Robust pis- ton design and optimization using piston secondary motion anal- ysis显示文摘 | Hoffmann R M SUDJIANTO A DU Xiaoping | 2003 | SAE Technical Paper Series2003，，： | 1 |
| 12 | Noise invalidation denoising 显示文摘 | BEHESHTI S HASHEMI M ZHANG Xiaoping | 2010 | IEEE Transactions on Signal Pro- cessing2010，58，12： | 1 |
| 13 | Adaptive denoising based on SURE risk显示文摘 | ZHANG Xiaoping DESAI M D | 1998 | IEEE Signal Processing Letters1998，5，10： | 1 |
| 14 | Inside-out, outside-in, and inside–outside-in: G protein signaling in integrin-mediated cell adhesion, spreading, and retraction显示文摘 | Bo Shen M Keegan Delaney Xiaoping Du | 2012 | Current Opinion in Cell Biology2012，，5： | 1 |
| 15 | Adaptive Denoising Based on SURE Risk显示文摘 | Zhang Xiaoping Desai M D | 1998 | IEEE Signal Processing Letters1998，5，10： | 1 |
| 16 | Design, synthesis, and eualutation of orally active 4-( 2,4-difuoro-5-( methoxycarbamoyl ) phenylamino ) pyrroolo triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors 显示文摘 | Robert M Borzilleri Xiaoping Zheng Lingang Qian | 2005 | J Med Chem2005，48，： | 1 |
| 17 | Social norms and cooperaion in social dilemmas:the effects of context and feedback显示文摘 | Madan M Pillutla Chen Xiaoping | 1999 | Organizational Behavior and Human Decision Processes1999，78，： | 1 |
| 18 | Adaptive denoising based on SURE risk显示文摘 | ZHANG XIAOPING DESAI M D | 1998 | IEEE Signal Processing Letters1998，5，10： | 1 |
| 19 | Comparative proteomic analysis of radiation-induced changes in mouse lung: fibrosis-sensitive and-resistant strains 显示文摘 | Xiaoping A O Lubman David M Davis Mary A | 2008 | Radiat Res2008，169，4： | 1 |
| 20 | Orthogonal Complex Filter Banks and Wavelets: Some Properties and Design显示文摘 | Z Xiaoping M Desai P Yingning | 1999 | IEEE Transactions on Signal Processing1999，47，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员